Prevymis (letermovir) - Merck (MSD)
An Update on the Efficacy and Safety Profile of 200-day Prevymis Therapy and Q&A (ICBMT 2025) - Sep 3, 2025 - Abstract #LS08; Pres time: Sep 12, 2025; 12:00 PM - 12:40 PM; "Sponsored by MSD Merck (MSD)" 
Clinical
https://pxpro.org/email/2025/ICBMT2025/data/ICBMT2025_abstract_book.pdf
 
Michelle Yong
 
Sep 3, 2025
 
Prev Next